FDA preps for upcoming ICCR
This article was originally published in The Rose Sheet
Executive Summary
Public meeting will be held June 19 in Rockville, Md. to provide information and receive comments related to International Cooperation on Cosmetics Regulations (ICCR), a voluntary effort between U.S., Japan, the EU and Canada to remove regulatory obstacles to international trade. FDA will go over topics to be discussed at second round of ICCR steering committee and expert working group meetings in Washington, D.C. the week of July 28, according to the agency's recent notice. In fall 2007, Senator John Kerry, D-Mass., lamented the public's exclusion from the first ICCR meeting in a letter to FDA Commissioner Andrew von Eschenbach (1"The Rose Sheet" Oct. 1, 2007, p. 3). An FDA document detailing the outcome of ICCR's first round of talks became available in March; FDA is accepting comments through July 2 (2"The Rose Sheet" March 10, 2008, In Brief)...
You may also be interested in...
Effort To Harmonize Cosmetics Regs Should Include Public Input – Sen. Kerry
FDA should take steps to ensure that the public can participate in an initiative to bring international cosmetics regulations closer to alignment, Senator John Kerry (D-Mass.) stated in a Sept. 26 letter to FDA Commissioner Andrew von Eschenbach
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.